Oculis Holding AG
OCS20.690USD
+0.210+1.03%
收盤 12/24, 13:00（美東）報價延遲15分鐘
1.16B總市值
虧損本益比TTM
關於 Oculis Holding AG 公司
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Oculis Holding AG簡介
公司代碼OCS
公司名稱Oculis Holding AG
上市日期Mar 03, 2023
CEOSherif (Riad)
員工數量49
證券類型Ordinary Share
年結日Mar 03
公司地址Bahnhofstrasse 20
城市ZUG
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Switzerland
郵編6300
電話41417113960
網址https://oculis.com/
公司代碼OCS
上市日期Mar 03, 2023
CEOSherif (Riad)
Oculis Holding AG公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Martijn Kleijwegt
Mr. Martijn Kleijwegt
Independent Director
Independent Director
470.97K
--
Mr. Pall Ragnar Johannesson
Mr. Pall Ragnar Johannesson
Chief Business Officer
Chief Business Officer
268.83K
+7.87%
Ms. Sylvia Cheung, CPA
Ms. Sylvia Cheung, CPA
Chief Financial Officer
Chief Financial Officer
72.06K
+7.86%
Ms. Geraldine O'Keeffe
Ms. Geraldine O'Keeffe
Independent Director
Independent Director
20.59K
--
Mr. Robert K. Warner
Mr. Robert K. Warner
Independent Director
Independent Director
--
--
Mr. Arshad M. Khanani, M.D.
Mr. Arshad M. Khanani, M.D.
Independent Director
Independent Director
--
--
Mr. Anthony A. (Tony) Rosenberg
Mr. Anthony A. (Tony) Rosenberg
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Riad Sherif, M.D.
Dr. Riad Sherif, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Christina M. Ackermann
Ms. Christina M. Ackermann
Independent Director
Independent Director
--
-100.00%
Mr. Lionel Carnot
Mr. Lionel Carnot
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Martijn Kleijwegt
Mr. Martijn Kleijwegt
Independent Director
Independent Director
470.97K
--
Mr. Pall Ragnar Johannesson
Mr. Pall Ragnar Johannesson
Chief Business Officer
Chief Business Officer
268.83K
+7.87%
Ms. Sylvia Cheung, CPA
Ms. Sylvia Cheung, CPA
Chief Financial Officer
Chief Financial Officer
72.06K
+7.86%
Ms. Geraldine O'Keeffe
Ms. Geraldine O'Keeffe
Independent Director
Independent Director
20.59K
--
Mr. Robert K. Warner
Mr. Robert K. Warner
Independent Director
Independent Director
--
--
Mr. Arshad M. Khanani, M.D.
Mr. Arshad M. Khanani, M.D.
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 12月2日 週二
更新時間: 12月2日 週二
持股股東
股東類型
持股股東
持股股東
佔比
EQT Partners AB
10.21%
EQT Life Sciences
9.95%
Earlybird Venture Capital
4.40%
Pivotal Bioventure Partners Investment Advisor LLC
3.98%
BVCF Management, Ltd.
3.79%
其他
67.67%
持股股東
持股股東
佔比
EQT Partners AB
10.21%
EQT Life Sciences
9.95%
Earlybird Venture Capital
4.40%
Pivotal Bioventure Partners Investment Advisor LLC
3.98%
BVCF Management, Ltd.
3.79%
其他
67.67%
股東類型
持股股東
佔比
Venture Capital
23.74%
Private Equity
10.21%
Investment Advisor/Hedge Fund
3.17%
Corporation
2.96%
Individual Investor
2.75%
Investment Advisor
1.68%
Hedge Fund
0.55%
Research Firm
0.07%
Bank and Trust
0.05%
其他
54.82%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
49
16.42M
28.41%
+792.94K
2025Q2
51
19.48M
37.42%
+1.76M
2025Q1
51
19.44M
37.35%
+1.93M
2024Q4
86
15.00M
31.97%
-10.87M
2024Q3
87
16.29M
41.43%
-9.17M
2024Q2
88
16.63M
42.28%
-9.14M
2024Q1
91
16.14M
42.22%
-11.25M
2023Q4
93
17.20M
46.87%
-6.97M
2023Q3
92
16.51M
48.34%
-4.37M
2023Q2
91
16.72M
48.91%
-4.14M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
EQT Life Sciences
5.75M
10.99%
+425.53K
+7.99%
Dec 31, 2024
Earlybird Venture Capital
2.54M
4.86%
+2.54M
--
Dec 31, 2024
Pivotal Bioventure Partners Investment Advisor LLC
2.30M
4.4%
--
--
Jun 30, 2025
BVCF Management, Ltd.
2.19M
4.19%
+121.79K
+5.88%
Nov 27, 2024
abrdn Inc.
1.25M
2.39%
--
--
Jun 30, 2025
Sherif (Riad M.D.)
644.75K
1.23%
-233.73K
-26.61%
Dec 31, 2024
Stefnir hf.
540.50K
1.03%
--
--
Aug 31, 2025
Nan Fung Life Sciences
514.70K
0.98%
--
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
Simplify Propel Opportunities ETF
2.81%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.12%
Even Herd Long Short ETF
0%
Simplify Propel Opportunities ETF
佔比2.81%
SPDR SSGA US Small Cap Low Volatility Index ETF
佔比0.12%
Even Herd Long Short ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Oculis Holding AG的前五大股東是誰？
Oculis Holding AG的前五大股東如下：
EQT Life Sciences持有股份：5.75M佔總股份比例：10.99%。
Earlybird Venture Capital持有股份：2.54M佔總股份比例：4.86%。
Pivotal Bioventure Partners Investment Advisor LLC持有股份：2.30M佔總股份比例：4.40%。
BVCF Management, Ltd.持有股份：2.19M佔總股份比例：4.19%。
abrdn Inc.持有股份：1.25M佔總股份比例：2.39%。
EQT Life Sciences持有股份：5.75M佔總股份比例：10.99%。
Earlybird Venture Capital持有股份：2.54M佔總股份比例：4.86%。
Pivotal Bioventure Partners Investment Advisor LLC持有股份：2.30M佔總股份比例：4.40%。
BVCF Management, Ltd.持有股份：2.19M佔總股份比例：4.19%。
abrdn Inc.持有股份：1.25M佔總股份比例：2.39%。
Oculis Holding AG的前三大股東類型是什麼？
Oculis Holding AG 的前三大股東類型分別是：
EQT Partners AB
EQT Life Sciences
Earlybird Venture Capital
EQT Partners AB
EQT Life Sciences
Earlybird Venture Capital
有多少機構持有Oculis Holding AG(OCS)的股份？
截至2025Q3，共有49家機構持有Oculis Holding AG的股份，合計持有的股份價值約為16.42M，占公司總股份的28.41% 。與2025Q2相比，機構持股有所增加，增幅為-9.01%。
哪個業務部門對Oculis Holding AG的收入貢獻最大？
在--，--業務部門對Oculis Holding AG的收入貢獻最大，創收--，占總收入的--% 。
